A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg (FINDER II)
Phase II Study to Evaluate the Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg in Postmenopausal Women With ER +ve Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy
Sponsor: AstraZeneca
This PHASE2 trial investigates Advanced Breast Cancer and Metastatic Breast Cancer and is currently completed. AstraZeneca leads this study, which shows 13 recorded versions since 2006 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Feb 2020 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 8 earlier versions
-
Jun 2019 — Feb 2020 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Mar 2019 — Jun 2019 [monthly]
Active Not Recruiting PHASE2
-
Nov 2018 — Mar 2019 [monthly]
Active Not Recruiting PHASE2
-
Jul 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Jan 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
May 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bordeaux, France , Brivé, France , Brussels, Belgium , Bucharest, Romania , Budapest, Hungary , Bydgoszcz, Poland , Cambridge, Canada , Cheb, Czechia , Clermont-Ferrand, France , Cluj-Napoca, Romania and 22 more locations